|
|
Biotech
|
|
||
Re: TA: CYTK- 1 x 18 chart - upcoming FDA meetingThe FDA plans to convene an Advisory Committee meeting for Cytokinetics Incorporated's (NASDAQ:CYTK) omecamtiv mecarbil marketing application. Omecamtiv mecarbil is an investigational, selective, small molecule cardiac myosin activator for heart failure with reduced ejection fraction. The FDA has assigned the application a standard review with a PDUFA target action date of November 30. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
41921 | Re: TA: CYTK- 1 x 18 chart - upcoming FDA meeting | lbl4321 | 3 | 5/26/2022 12:20:56 PM |